



**Chelsea and Westminster Hospital NHS Foundation Trust
Trust Medicines Group**

Summary of Main Points from the Meeting held on Monday 9th October 2017

2. Minutes and Summary Notes from last meeting

The Minutes and Summary notes from the September 2017 Medicines Group meeting were approved and will be circulated.

3. Matters Arising

The Group noted the matters arising from the previous meeting.

4. Business to be transacted by the Medicines Group

4.1 Formulary Applications

Full Applications

Nil

Ex-Panel Requests

• **Infanrix-hexa[®] 6-in-1 Vaccine**

6 in 1 vaccine (Diphtheria; Tetanus; Poliomyelitis; Pertussis; Haemophilus Influenzae Type B and Hepatitis B) which now forms part of the NHS childhood vaccine programme for babies born after 1st August 2017

Decision: Approved for addition to the formulary

NICE Approved drug applications

• **Carfilzomib - In line with TA457 for previously treated multiple myeloma**

Approved by NICE in July 2017

Decision: Approved for addition to the formulary

• **Roflumilast - In line with TA461 for treating chronic obstructive pulmonary disease**

Approved by NICE in July 2017

Decision: Approved for addition to the formulary

Action: To confirm that these will be added to NWLIF and ongoing prescribing will be undertaken by GP in Primary Care.

• **Cabozantinib - in line with TA463 for previously treated advanced renal cell carcinoma**

Approved by NICE in August 2017

Decision: Approved for addition to the formulary

• **Baricitinib - In line with TA466 for moderate to severe rheumatoid arthritis**

Approved by NICE in August 2017

Decision: Approved for addition to the formulary

• **Eluxadoline - In line with TA471 for treating irritable bowel syndrome with diarrhoea**

Approved by NICE in August 2017

Decision: Approved for addition to the formulary

Action: To confirm that these will be added to NWLIF and ongoing prescribing will be undertaken by GP in Primary Care.

• **Obinutuzumab - In line with TA472 with bendamustine for treating follicular lymphoma refractory to rituximab**

Approved by NICE in August 2017

Decision: Approved for addition to the formulary

Pharmacoeconomic Board requests

• **Ceftolozane/Tazobactam IV for Pseudomonal Infection**

Approved by the Pharmacoeconomic Board on 11/09/17

Decision: Noted



Chelsea and Westminster Hospital NHS Foundation Trust Trust Medicines Group

4.2 Trust Medicines Policy

• TMP: Section 2 - Prescribing

Clear description of where Target INR and indication for warfarin is documented following the Trust Medicines Policy Audit 2017.

Decision: Approved

• TMP: Section 6 - Controlled drugs

Updated to state that controlled drug safes do not need to be located within a cabinet.

Deregulation of all PDE inhibitors

Clarity added regarding management of refused doses at ward/department level

Decision: Approved

• TMP: Section 21 - Patient Group Directions

Amendments:

- Audit section made clearer.
- Addition of a competency assessment sheet (Appendix 21.2)
- Updated audit tool (Appendix 21.8)
- Update of section relating to Clinical Trials
- Removal of the need to reconcile incoming and out-going PGD stock on a patient by patient basis. (This was originally listed as additional guidance in HSC 2000/026 and does not feature in NICE Guidance (Patient Group Directions) August 2013)
- Removal of the PGD stock reconciliation form

Decision: Approved

4.3 Medicines Optimisation

• Rituximab IV Administration chart

Update chart:

- o Brand annotation added
- o Addition of pre-rituximab screening to include hepatology/anti-viral treatment review
- o Addition of pre-rituximab screening to include checking of immunoglobulin
- o Addition of pre-rituximab screening to include checking of the patient's pneumococcal and annual flu vaccination details
- o Comment to highlight that all patients should receive paracetamol and chlorpheniramine prior to Rituximab infusion.

Some comments received regarding:

- **Why is there a need for IG monitoring?**
- **Who is responsibility to undertaking the check of annual influenza vaccination?**
- **Who is responsible for completing the Brand name?**

Decision: Await feedback from Rheumatology

4.4 NICE TA Guidance

NICE TA Guidance - September 2017

3 Appraisals were published in September 2017

TA474 - Sorafenib for treating advanced hepatocellular carcinoma

Formulary status

Not relevant to C&W.

TA475 - Dimethyl fumarate for treating moderate to severe plaque psoriasis

Formulary status

Currently included on formulary

TA476 - Paclitaxel as albumin-bound nanoparticles with gemcitabine for untreated metastatic pancreatic cancer

Formulary status



**Chelsea and Westminster Hospital NHS Foundation Trust
Trust Medicines Group**

To confirm if this is relevant to C&W.

4.5 IVIG Update

- **IVIG requests**

September 2017

CWH Site

There were 18 IVIG issues in September 2017, with 6 new requests

WMUH Site

There were 16 IVIG issues in September 2017, with 1 new request

Decision: Approved

- **Vigam Infusion administration sheet**

Updated

Decision: Approved

- **Privigen infusion administration sheet**

Updated

Decision: Approved

- **Kiovig infusion administration sheet**

Updated

Decision: Approved

- **Trust IV Administration Guide - Immunoglobulin Infusion**

Updated

Decision: Approved

- **Immunoglobulin Request Form**

Updated

Decision: Approved

4.6 Items for noting

- **NHS England Provided letter re. Adalimumab for Severe refractory uveitis**

NHS Provider letter in relation to NICE TA460

Decision: Noted

- **Terms of Reference: Trust Medicines Safety Group**

Terms of Reference for Trust Medicines Safety Group

Decision: Noted

- **Terms of Reference: Antimicrobial Steering Group**

Terms of Reference for Trust Antimicrobial Steering Group

Decision: Noted

- **Terms of Reference: Clinical Directorate of HIV and GUM, Medicines Sub-Group**

Terms of Reference Clinical Directorate of HIV and GUM, Medicines Sub-Group

Decision: Noted

- **Trust NMP Register**

Trust Non-Medical Prescribing Register as at September 2017

Decision: Noted

- **MHRA Drug Safety Update - September 2017**

Decision: Noted



**Chelsea and Westminster Hospital NHS Foundation Trust
Trust Medicines Group**

4.7 Meeting minutes for noting

• **Trust Medicines Safety Group Meeting - July 2017**

Minutes for Trust Medicines Safety Group Meeting - July 2017

Decision: Noted

• **Trust Medicines Safety Group Meeting - August 2017**

Minutes for Trust Medicines Safety Group Meeting - August 2017

Decision: Noted

4.8 Additional papers to go to Trust patient Safety Group

Nil

5. Any other business

5.1 Items which should not routinely be prescribed in primary care: A consultation on guidance for CCGs

6. Date of next meeting

Date: Monday 13th November 2017

Time: 8am-9am

Location: Board Room (CWH Site) and Meeting Room A (WMUH Site via video conferencing)

Closing date: 20th October 2017